FDA official logo
GSRS logoPFDA official logo

ELZOCABTAGENE AUTOLEUCEL

UNII:T2ZFF62NQ9
Type:INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:ELZOCABTAGENE AUTOLEUCEL
GSRS Full Record:
T2ZFF62NQ9
i

  • Elzocabtagene Autoleucel
  • autologous T lymphocytes from peripheral blood obtained by leukapheresis, transduced with four self-inactivating, nonreplicating lentiviral vectors encoding (i) a chimeric antigen receptor (CAR) targeting guanylyl cyclase C (GC-C, GUCY2C), (ii) a chimeric antigen receptor (CAR) targeting CD19 co-expressing interferon gamma (IFN-γ), (iii) a chimeric antigen receptor (CAR) targeting CD19 co-expressing interleukin-6 (IL-6), (iv) a chimeric antigen receptor (CAR) targeting CD19 co-expressing interleukin-12 (IL-12) fused to a von Hippel-Lindau tumour suppressor (VHL) recognition sequence. Each CAR transgene comprises a signal peptide derived from the CD8 alpha chain, a single chain variable fragment (scFv) binding domain, a CD8 hinge and transmembrane domain, a 4-1BB costimulatory domain and a CD3ζ signalling domain, under control of the human elongation factor 1 alpha (EF-1α) core promoter. For the three vectors that also encode a cytokine, each cytokine gene is preceded by an NFAT enhancer and is under the control of a minimal IL-2 promoter. For the IL-12-VHL expressing vector, a recognition sequence of the von Hippel-Lindau tumour suppressor protein (VHL) is fused to the 3' end of the IL-12 gene via an EA rich linker. Each construct is flanked by 5' and 3' long terminal repeats (LTRs) and also contains a ψ packaging signal, a Rev response element (RRE), a central polypurine tract (CPPT) and central termination sequence (CTS) and a Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). Each vector is pseudotyped with the vesicular stomatitis virus (VSV) G envelope protein. The leukapheresis material is enriched for CD4/CD8 T lymphocytes by positive immunoselection, activated by CD3 and CD28 agonists and transduced with the vector. The cells are then expanded in media with serum replacement and interleukin 2 (IL-2). The T lymphocytes (>75%) are positive for the transgenes (>5% CAR positive), with less than 0.5 % CD19+ cells. The cells produce cytokines (interleukin-6, interleukin-12, and interferon gamma) in co-culture with B lymphocytes
  • elzocabtagene autoleucel [INN]




UNII - T2ZFF62NQ9 | UNII Search Service